Antihypertensive Drugs and Lip Cancer in Non-Hispanic Whites

Authors:

Abstract
In screening pharmaceuticals for possible carcinogenic effects, an increased risk of cancer of the lip was identified in persons who received 3 or more prescriptions of the diuretic hydrochlorothiazide and the calcium channel blocker nifedipine.1 A causal relationship is biologically plausible because sun exposure is an established risk factor for lip cancer2 and hydrochlorothiazide and nifedipine are photosensitizers.3,4 For the present study, we conducted more extensive analyses of the risk of lip cancer in relation to hydrochlorothiazide, nifedipine, and the following other commonly used antihypertensive drugs: the combination of hydrochlorothiazide with triamterene, a potassium-sparing diuretic; lisinopril, an angiotensin-converting enzyme inhibitor; and atenolol, a β-adrenergic blocker. In addition to hydrochlorothiazide and nifedipine, triamterene is an established photosensitizer, and lisinopril is likely to be a photosensitizer; atenolol is not recognized as such.4,5 Associations were analyzed by the number of prescriptions received and duration of use of the drug with adjustment for cigarette smoking, a known risk factor for lip cancer.

This publication has 30 references indexed in Scilit: